U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H20N2S
Molecular Weight 284.4208
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROMETHAZINE

SMILES

CC(CN1c2ccccc2Sc3ccccc31)N(C)C

InChI

InChIKey=PWWVAXIEGOYWEE-UHFFFAOYSA-N
InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C17H20N2S
Molecular Weight 284.4208
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Promethazine is a phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

1.29219835E12
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

1.29219835E12
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

1.29219835E12
Preventing
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

1.29219835E12
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

1.29219835E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.2 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 ng/mL
12.5 mg single, intravenous
dose: 12.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.28 ng/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
21.84 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
48.26 ng/mL
50 mg single, intramuscular
dose: 50 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.75 ng/mL
25 mg single, rectal
dose: 25 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
19.3 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.04 ng/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11511 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14466 ng × h/mL
12.5 mg single, intravenous
dose: 12.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
146.62 ng × h/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
180.14 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
627.13 ng × h/mL
50 mg single, intramuscular
dose: 50 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
146 ng × h/mL
25 mg single, rectal
dose: 25 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
361 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
256 ng × h/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.2 h
12.5 mg single, intravenous
dose: 12.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17.7 h
25 mg single, rectal
dose: 25 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18.6 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17.2 h
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Disc. AE: Sinus tachycardia, Consciousness decreased...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia
Consciousness decreased
Agitation
Confusion
Disorientation
Visual hallucinations
Delirium
Sources: Page: p.242
160 mg single, intramuscular
Highest studied dose
Dose: 160 mg
Route: intramuscular
Route: single
Dose: 160 mg
Sources: Page: p.199
healthy, 21.4±1.7
n = 6
Health Status: healthy
Age Group: 21.4±1.7
Sex: M+F
Population Size: 6
Sources: Page: p.199
120 mg single, intramuscular
Higher than recommended
Dose: 120 mg
Route: intramuscular
Route: single
Dose: 120 mg
Sources: Page: p.199
healthy, 22.7±2.31
n = 10
Health Status: healthy
Age Group: 22.7±2.31
Sex: M+F
Population Size: 10
Sources: Page: p.199
80 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 80 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.199
healthy, 24.2±1.17
n = 10
Health Status: healthy
Age Group: 24.2±1.17
Sex: M+F
Population Size: 10
Sources: Page: p.199
50 mg single, intramuscular|intravenous (max)
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Allergic Conditions|Nausea and Vomiting|Sedation
Sources: Page: p.1
Disc. AE: Respiratory depression, Irritation skin...
AEs leading to
discontinuation/dose reduction:
Respiratory depression (grade 5)
Irritation skin (severe)
Pain
Thrombophlebitis
Sources: Page: p.1
50 mg single, oral (max)
Recommended
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources: Page: p.2, 3
unhealthy
Health Status: unhealthy
Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation
Sources: Page: p.2, 3
Disc. AE: Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Respiratory depression (grade 5)
Sources: Page: p.2, 3
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Confusion Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Consciousness decreased Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Delirium Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Disorientation Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Sinus tachycardia Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Visual hallucinations Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Co-administed with::
cyproheptadine, p.o(200 mg, single)
Sources: Page: p.242
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 14
Sex: F
Population Size: 1
Sources: Page: p.242
Pain Disc. AE
50 mg single, intramuscular|intravenous (max)
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Allergic Conditions|Nausea and Vomiting|Sedation
Sources: Page: p.1
Thrombophlebitis Disc. AE
50 mg single, intramuscular|intravenous (max)
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Allergic Conditions|Nausea and Vomiting|Sedation
Sources: Page: p.1
Respiratory depression grade 5
Disc. AE
50 mg single, intramuscular|intravenous (max)
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Allergic Conditions|Nausea and Vomiting|Sedation
Sources: Page: p.1
Irritation skin severe
Disc. AE
50 mg single, intramuscular|intravenous (max)
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Allergic Conditions|Nausea and Vomiting|Sedation
Sources: Page: p.1
Respiratory depression grade 5
Disc. AE
50 mg single, oral (max)
Recommended
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources: Page: p.2, 3
unhealthy
Health Status: unhealthy
Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation
Sources: Page: p.2, 3
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 32 uM]
yes [Inhibition 88 uM]
Drug as victim

Drug as victim

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.
2001
[Work time distribution in night shift: are clinics facing a adjustment boom?].
2001 Jul
[The activity of enzymes and free radical oxidation in acute and chronic fetal hypoxia in general anesthesia during cesarean section].
2002
Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.
2002
[Suicidal attempts with old (currently unused) drug].
2002
Antiallergic anti-inflammatory effects of H1-antihistamines in humans.
2002
Investigation of the effect of tablet surface area/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets.
2002 Apr
Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction.
2002 Apr
A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis.
2002 Apr
Study of the stability of promethazine enantiomers by liquid chromatography using a vancomycin-bonded chiral stationary phase.
2002 Apr 25
A systematic approach to the management of postoperative nausea and vomiting.
2002 Dec
Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes.
2002 Feb
Cold temperatures reduce the sensitivity of stored platelets to disaggregating agents.
2002 Feb
An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers.
2002 Jan
[A case of fluvoxamine overdose].
2002 Jan
Investigation of interaction of promethazine with cyclodextrins.
2002 Jan-Feb
Bradykinin is involved in hyperalgesia induced by Bothrops jararaca venom.
2002 Jul
Recovery, enrichment and selectivity in liquid-phase microextraction comparison with conventional liquid-liquid extraction.
2002 Jul 19
Project USAP 2000--use of sedative agents by pediatric dentists: a 15-year follow-up survey.
2002 Jul-Aug
Fibromyositis after intramuscular pentazocine abuse.
2002 Jul-Sep
In vitro reversal of chloroquine resistance in Plasmodium falciparum with dihydroethanoanthracene derivatives.
2002 Jun
Indirect spectrophotometric determination of propranolol hydrochloride and piroxicam in pure and pharmaceutical formulations.
2002 Jun
Central effects of cinnarizine: restricted use in aircrew.
2002 Jun
Next generation antihistamines: therapeutic rationale, accomplishments and advances.
2002 Jun
Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay.
2002 Jun 19
The effect of meperidine and promethazine on fetal heart rate indices during the active phase of labor.
2002 Mar
Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents.
2002 Mar-Apr
Liquid-phase microextraction of protein-bound drugs under non-equilibrium conditions.
2002 May
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial.
2002 May
Simultaneous determination of promethazine, chlorpromazine, and perphenazine by multivariate calibration methods and derivative spectrophotometry.
2002 May-Jun
Effect of some psychotropic drugs on luminol-dependent chemiluminescence induced by O2-, *OH, HOCl.
2002 Nov-Dec
Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians.
2002 Nov-Dec
Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase.
2002 Oct
Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine.
2002 Oct
Acute allergic reaction following contact with a spider.
2002 Oct
TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243].
2002 Oct 16
[Landau-Kleffner and autistic regression: the importance of differential diagnosis].
2002 Sep
A case of homicide by lethal injection with lidocaine.
2002 Sep
Enantioseparation of phenothiazines in cyclodextrin-modified micellar electrokinetic chromatography.
2002 Sep 20
Interaction between various resistance modifiers and apoptosis inducer 12H-benzo[alpha]phenothiazine.
2002 Sep-Oct
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers.
2003 Apr
Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view.
2003 Apr
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
2003 Apr
Inactivation of cholinesterase induced by chlorpromazine cation radicals.
2003 Feb
Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages.
2003 Feb
Reye's syndrome: down but not out.
2003 Jan
Interaction of carbamazepine and promethazine in rabbits.
2003 Jan
Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers.
2003 Mar
Clinical practice. Vestibular neuritis.
2003 Mar 13
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.
2003 May
Patents

Sample Use Guides

Allergy: the average oral dose is 25 mg taken before retiring; however, 12.5 mg may be taken before meals and on retiring, if necessary. Single 25 mg doses at bedtime or 6.25 to 12.5 mg taken three times daily will usually suffice. After initiation of treatment in children or adults, dosage should be adjusted to the smallest amount adequate to relieve symptoms. The administration of promethazine HCI in 25 mg doses will control minor transfusion reactions of an allergic nature. Motion Sickness: the average adult dose is 25 mg taken twice daily. The initial dose should be taken one-half to one hour before anticipated travel and be repeated 8 to 12 hours later, if necessary. On succeeding days of travel, it is recommended that 25 mg be taken on arising and again before the evening meal. For children, 12.5 to 25 mg, twice daily, may be administered. Nausea and Vomiting: antiemetics should not be used in vomiting of unknown etiology in children and adolescents. The average effective dose of Promethazine HCL Oral Solution for the active therapy of nausea and vomiting in children or adults is 25 mg. When oral medication cannot be tolerated, the dose should be given parenterally or by rectal suppository. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. For nausea and vomiting in children, the usual dose is 0.5 mg per pound of body weight, and the dose should be adjusted to the age and weight of the patient and the severity of the condition being treated. For prophylaxis of nausea and vomiting, as during surgery and the postoperative period, the average dose is 25 mg repeated at 4 to 6 hour intervals, as necessary. Sedation: this product relieves apprehension and induces a quiet sleep from which the patient can be easily aroused. Administration of 12.5 to 25 mg Promethazine HCl Oral Solution by the oral route will provide sedation in children. Adults usually require 25 to 50 mg for nighttime, presurgical, or obstetrical sedation. Pre- and Postoperative Use: promethazine HCl Oral Solution in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. For preoperative medication, children require doses of 0.5 mg per pound of body weight in combination with an appropriately reduced dose of narcotic or barbiturate and the appropriate dose of an atropine-like drug. Usual adult dosage is 50 mg Promethazine HCl Oral Solution with an appropriately reduced dose of narcotic or barbiturate and the required amount of a belladonna alkaloid. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults. Promethazine HCL Oral Solution is contraindicated for children under 2 years of age.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:22:46 UTC 2021
Edited
by admin
on Sat Jun 26 05:22:46 UTC 2021
Record UNII
FF28EJQ494
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROMETHAZINE
HSDB   INN   JAN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
PROMETHAZINE [INN]
Common Name English
FARGAN
Brand Name English
N-(2'-DIMETHYLAMINO-2'-METHYL)ETHYLPHENOTHIAZINE
Common Name English
PROMETHAZINE [VANDF]
Common Name English
PROMETHAZINE [HSDB]
Common Name English
10-(2-DIMETHYLAMINOPROPYL)PHENOTHIAZINE
Systematic Name English
PROMETHAZINE [JAN]
Common Name English
DIMAPP
Brand Name English
N,N,.ALPHA.-TRIMETHYL-10H-PHENOTHIAZINE-10-ETHANAMINE
Systematic Name English
10-(2-DIMETHYLAMINO-2-METHYLETHYL)PHENOTHIAZINE
Systematic Name English
RP-3277
Code English
DIPHERGAN
Brand Name English
PROTHAZIN
Brand Name English
10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,.ALPHA.-TRIMETHYL-
Systematic Name English
PROMETAZIN
Brand Name English
PROCIT
Brand Name English
PROMETHAZINE [MI]
Common Name English
PROMETHAZINE [WHO-DD]
Common Name English
10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,.ALPHA.-TRIMETHYL-, (+/-)-
Systematic Name English
PROMETHAZINE [MART.]
Common Name English
PROAZAMINE
Common Name English
PHENOTHIAZINE, 10-(2-(DIMETHYLAMINO)PROPYL)-
Systematic Name English
NSC-30321
Code English
PROTAZINE
Brand Name English
(+/-)-10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE
Systematic Name English
VALLERGINE
Brand Name English
Classification Tree Code System Code
WHO-VATC QR06AD52
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
WHO-ATC V03AB05
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
WHO-ATC R06AD52
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
NCI_THESAURUS C740
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
NDF-RT N0000007544
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
NDF-RT N0000175746
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
NDF-RT N0000007544
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
LIVERTOX 805
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
WHO-VATC QD04AA10
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
NDF-RT N0000007544
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
WHO-ATC D04AA10
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
WHO-VATC QR06AD02
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
WHO-ATC R06AD02
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
WHO-VATC QV03AB05
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
Code System Code Type Description
CAS
73745-50-3
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
SUPERSEDED
DRUG BANK
DB01069
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
WIKIPEDIA
PROMETHAZINE
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
MERCK INDEX
M9171
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
200-489-2
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
EPA CompTox
60-87-7
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
EVMPD
SUB10088MIG
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
NCI_THESAURUS
C779
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
CAS
60-87-7
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
DRUG CENTRAL
2286
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
HSDB
3173
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
INN
516
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
IUPHAR
7282
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL643
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
MESH
D011398
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
RXCUI
8745
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY RxNorm
PUBCHEM
4927
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
FDA UNII
FF28EJQ494
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
LACTMED
Promethazine
Created by admin on Sat Jun 26 05:22:47 UTC 2021 , Edited by admin on Sat Jun 26 05:22:47 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC